Effects of Phospholipid-Coated Extracorporeal Circuits on Clinical Outcome Parameters and Systemic Inflammatory Response in Coronary Artery Bypass Graft Patients
DOI:
https://doi.org/10.1532/hsf.1095Abstract
Introduction: The use of extracorporeal circulation (ECC) during coronary artery bypass graft (CABG) surgery is associated with a systemic inflammatory response due to the contact of blood with artificial surfaces. The clinical relevance of ECC-related systemic inflammation varies with the patient, and such inflammation may be accompanied by intermittent organ dysfunction and an increased catecholamine requirement. We investigated the effects of a new phospholipid coating system of ECC on systemic inflammatory response and clinical outcome following CABG.
Methods: Patients scheduled for CABG surgery were prospectively divided randomly into 2 patient groups: patients using noncoated ECC materials and patients using phospholipid-coated ECC materials. Clinical data measured perioperatively included hemodynamics, aortic clamp time, duration of bypass, time to extubation, catecholamine requirement, length of intensive care unit (ICU) stay, postoperative blood loss, and amount of blood transfused. In addition, blood samples were collected before cannulation and at 2, 24, and 48 hours postoperative. Cytokines (tumor necrosis factor 3 [TNF-3] and interleukin 10 [IL-10]) and P-selectin were measured with an enzyme-linked immunosorbent assay. Plasma nitrate/nitrite levels (NOx) were determined by the Griess reaction.
Results: A significant increase of TNF-3 level was noted in the uncoated control group only. In the uncoated group, IL-10 levels significantly increased at 2 hours postoperative, whereas levels remained unchanged in the phospholipid coating group. P-selectin increased 2 hours postoperative in the uncoated group, and no significant changes were noted in the phospholipid coating group. At 24 hours postoperative, total plasma NOx production significantly increased in the phospholipid coating group but remained constant in the control group. No significant differences with respect to postoperative parameters (time to extubation, ICU stay, amount of bleeding, blood transfused, and catecholamine requirement) were observed.
Conclusions: Phospholipid coating significantly reduces the systemic increase in proinflammatory and anti-inflammatory cytokines and P-selectin. Despite the comparable clinical outcomes in this study, the observed significant reduction in systemic inflammatory parameter values suggests an improved biocompatibility of ECC materials when they are coated with phospholipids.
References
Op den Kamp J. 1979. Lipid asymmetry in membranes. Ann Rev Biochem 48:47-71.nPenttila H, Lepojarvi M, Kiviluoma K, Kaukoranta P, Hassinen I, Peuhkurinen K. 2001. Myocardial preservation during coronary surgery with and without cardiopulmonary bypass. Ann Thorac Surg 71:565-71.nRidker P, Buring J, Rifai N. 2001. Soluble P-selectin and risk for future events. Circulation 103:491-5.nScherphof G, Van Leeuwen B, Wilschut J, Damen J. 1983. Exchange of phosphatidylcholine between small unilamellar liposomes and human plasma high-density lipoprotein involves exclusively the phospholipid in the outer monolayer of the liposomal membrane. Biochim Biophys Acta 732:595-9.nSteinberg J, Kapelanski D, Olson J, Weiler J. 1993. Cytokines and complement levels in patients undergoing cardiopulmonary bypass. J Thorac Cardiovasc Surg 106:1008-16.nWan S, Izzat M, Lee T, Wan I, Tang N, Yim A. 1999. Avoiding cardiopulmonary bypass in multivessel CABG reduces cytokine response and myocardial injury. Ann Thorac Surg 68:52-6.nWan S, LeClerc J, Vincent J. 1997. Inflammatory response to cardiopulmonary bypass: mechanisms involved and possible therapeutic strategies. Chest 112:676-92.nWei M, Kuukasjarvi, Laurikka J, et al. 2001. Cytokine response in low-risk coronary artery bypass surgery. Int J Angiol 10:27-30.nWildhirt S, Schulze C, Conrad N, et al. 2000. Reduced myocardial cellular damage and lipid peroxidation in off-pump versus conventional coronary artery bypass grafting. Eur J Med Res 5:222-8.nWildhirt S, Schulze C, Schulz C, et al. 2001. Systemic and cardiac adhesion molecule expression after off-pump versus conventional coronary artery bypass grafting. Shock 16(suppl):55-9.nZuo Z, Wang C, Carpenter D, et al. 2001. Prolongation of allograft survival with viral IL-10 transfection in a highly histoincompatible model of rat heart allograft rejection. Transplantation 71:686-91.nBirks EJ, Yacoub MH. 1997. The role of nitric oxide and cytokines in heart failure. Coron Artery Dis 8:389-402.nCremer J, Martin M, Redl H, et al. 1996. Systemic inflammatory response after cardiac operations. Ann Thorac Surg 61:1714-20.nCzerny M, Baumer H, Kilo J, et al. 2000. Inflammatory response and myocardial injury following coronary artery bypass grafting with or without cardiopulmonary bypass. Eur J Cardiothorac Surg 17:737-42.nDe Somer F, Francois K, van Oeveren W, et al. 2000. Phosphorylcholine coating of extracorporeal circuits provides natural protection against blood activation by the material surface. Eur J Cardiothorac Surg 18:602-6.nDe Somer F, Van Belleghem Y, Foubert L, et al. 1999. In vivo evaluation of a phosphorylcholine coated cardiopulmonary bypass circuit. J Extra Corpor Technol 31:62-6.nDiegeler A, Doll N, Rauch T, et al. 2000. Humoral immune response during coronary artery bypass grafting: a comparison of limited approach, "off-pump" technique, and conventional cardiopulmonary bypass. Circulation 102(suppl 3):95-100.nFernando R, Chan R. 2000. Anti-inflammatory pre-treatment and the resultant effects of interleukin-10: adjuncts to multi-therapeutical strategies. Perfusion 15:501-5.nFerrari R, Bachetti T, Confortini R, et al. 1995. Tumor necrosis factor soluble receptors in patients with congestive heart failure. Circulation 92:1479-86.nHayward J, Durrani A, Lu Y, Clayton C, Chapman D. 1986. Biomembranes as models for polymer surfaces, IV: ESCA analyses of a phosphorylcholine surface covalently bound to hydroxylated substrates. Biomaterials 7:252-8.nJones S, Trocha S, Lefer D. 2001. Cardioprotective actions of endogenous IL-10 are independent of iNOS. Am J Physiol Heart Circ Physiol 281:H48-52.nKapadia S. 1999. Cytokines and heart failure. Cardiol Rev 7:196-206. Lorant DE, Topham MK, Whatley MK, et al. 1993. Inflammatory roles of P-selectin. J Clin Invest 92:559-70.n
Published
How to Cite
Issue
Section
Author Disclosure & Copyright Transfer Agreement
In order to publish the original work of another person(s), The Heart Surgery Forum® must receive an acknowledgment of the Author Agreement and Copyright Transfer Statement transferring to Forum Multimedia Publishing, L.L.C., a subsidiary of Carden Jennings Publishing Co., Ltd. the exclusive rights to print and distribute the author(s) work in all media forms. Failure to check Copyright Transfer agreement box below will delay publication of the manuscript.
A current form follows:
The author(s) hereby transfer(s), assign(s), or otherwise convey(s) all copyright ownership of the manuscript submitted to Forum Multimedia Publishing, LLC (Publisher). The copyright transfer covers the exclusive rights to reproduce and distribute the article and the material contained therein throughout the world in all languages and in all media of expression now known or later developed, including but not limited to reprints, photographic reproduction, microfilm, electronic data processing (including programming, storage, and transmission to other electronic data record(s), or any other reproductions of similar nature), and translations.
However, Publisher grants back to the author(s) the following:
- The right to make and distribute copies of all or part of this work for use of the author(s) in teaching;
- The right to use, after publication in The Heart Surgery Forum, all or part of the material from this work in a book by the author(s), or in a collection of work by the author(s);
- The royalty-free right to make copies of this work for internal distribution within the institution/company that employs the author(s) subject to the provisions below for a work-made-for-hire;
- The right to use figures and tables from this work, and up to 250 words of text, for any purpose;
- The right to make oral presentations of material from this work.
Publisher reserves the right to grant or refuse permission to third parties to republish all or part of the article or translations thereof. To republish, such third parties must obtain written permission from the Publisher. (This is in accordance with the Copyright Statute, United States Code, Title 17. Exception: If all authors were bona fide officers or employees of the U.S. Government at the time the paper was prepared, the work is a “work of the US Government” (prepared by an officer or employee of the US Government as part of official duties), and therefore is not subject to US copyright; such exception should be indicated on signature lines. If this work was prepared under US Government contract or grant, the US Government may reproduce, royalty-free, all or portions of this work and may authorize others to do so, for official US Government purposes only, if the US Government contract or grant so requires.
I have participated in the conception and design of this work and in the writing of the manuscript and take public responsibility for it. Neither this manuscript nor one with substantially similar content under my authorship has been published, has been submitted for publication elsewhere, or will be submitted for publication elsewhere while under consideration by The Heart Surgery Forum, except as described in an attachment. I have reviewed this manuscript (original version) and approve its submission. If I am listed above as corresponding author, I will provide all authors with information regarding this manuscript and will obtain their approval before submitting any revision. I attest to the validity, accuracy, and legitimacy of the content of the manuscript and understand that Publisher assumes no responsibility for the validity, accuracy, and legitimacy of its content. I warrant that this manuscript is original with me and that I have full power to make this Agreement. I warrant that it contains no matter that is libelous or otherwise unlawful or that invades individual privacy or infringes any copyright or other proprietary right. I agree to indemnify and hold Publisher harmless of and from any claim made against Publisher that relates to or arises out of the publication of the manuscript and agree that this indemnification shall include payment of all costs and expenses relating to the defense of any such claim, including all reasonable attorney’s fees.
I warrant that I have no financial interest in the drugs, devices, or procedures described in the manuscript (except as disclosed in the attached statement).
I state that the institutional Human Subjects Committee and/or the Ethics Committee approved the clinical protocol reported in this manuscript for the use of experimental techniques, drugs, or devices in human subjects and appropriate informed consent documents were utilized.
Furthermore, I state that any and all animals used for experimental purposes received humane care in USDA registered facilities in compliance with the “Principles of Laboratory Animal Care” formulated by the National Society for Medical Research and the “Guide for the Care and Use of Laboratory Animals” prepared by the Institute of Laboratory Animal Resources and published by the National Institutes of Health (NIH Publication No. 85-23, revised 1985).
